ATE529402T1 - 3',6-substituierte indirubine und ihre biologischen anwendungen - Google Patents

3',6-substituierte indirubine und ihre biologischen anwendungen

Info

Publication number
ATE529402T1
ATE529402T1 AT08161646T AT08161646T ATE529402T1 AT E529402 T1 ATE529402 T1 AT E529402T1 AT 08161646 T AT08161646 T AT 08161646T AT 08161646 T AT08161646 T AT 08161646T AT E529402 T1 ATE529402 T1 AT E529402T1
Authority
AT
Austria
Prior art keywords
biological applications
substituted
halogen
alkyl
indirubins
Prior art date
Application number
AT08161646T
Other languages
English (en)
Inventor
Laurent Meijer
Leandros Skaltsounis
Emmanuel Mikros
Prokopios Magiatis
Carl Johnson
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE529402T1 publication Critical patent/ATE529402T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT08161646T 2008-08-01 2008-08-01 3',6-substituierte indirubine und ihre biologischen anwendungen ATE529402T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161646A EP2149553B1 (de) 2008-08-01 2008-08-01 3',6-substituierte Indirubine und ihre biologischen Anwendungen

Publications (1)

Publication Number Publication Date
ATE529402T1 true ATE529402T1 (de) 2011-11-15

Family

ID=40225521

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08161646T ATE529402T1 (de) 2008-08-01 2008-08-01 3',6-substituierte indirubine und ihre biologischen anwendungen
AT09802595T ATE547401T1 (de) 2008-08-01 2009-07-21 3',6-substituierte indirubine und ihre biologische anwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT09802595T ATE547401T1 (de) 2008-08-01 2009-07-21 3',6-substituierte indirubine und ihre biologische anwendung

Country Status (6)

Country Link
US (1) US8829203B2 (de)
EP (2) EP2149553B1 (de)
JP (1) JP5577336B2 (de)
AT (2) ATE529402T1 (de)
CA (1) CA2732232C (de)
WO (1) WO2010013168A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5448455B2 (ja) * 2005-12-23 2014-03-19 サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク （セ エン エール エス） 新規３’−，７−置換インジルビンおよびそれらの適用
EP2149553B1 (de) 2008-08-01 2011-10-19 Centre National de la Recherche Scientifique 3',6-substituierte Indirubine und ihre biologischen Anwendungen
EP2451836A1 (de) 2009-07-08 2012-05-16 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren zur induzierung von erweiterter selbsterneuerung von funktional differenzierten körperzellen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2733140A4 (de) * 2011-07-15 2014-11-26 Univ Nihon Indirubinderivat mit hochselektiver zytotoxizität für bösartige tumore
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9512076B2 (en) 2012-02-03 2016-12-06 City Of Hope Indirubin derivatives and uses thereof in treating chronic myelogenous leukemia
US10435367B2 (en) * 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof
AU2013234955A1 (en) 2012-03-23 2014-11-13 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
BR112015023383A2 (pt) * 2013-03-14 2017-07-18 Hope City compostocomposição farmacêutica; e método de modulação
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
JP7005779B2 (ja) * 2017-10-31 2022-02-10 ペレメッド カンパニー リミテッド 急性骨髄性白血病又は転移性乳癌の予防又は治療用薬剤学的組成物
US12303490B2 (en) 2019-11-04 2025-05-20 Ck Regeon Inc. Compositions and methods for suppressing and/or treating neurodegenerative diseases and/or a clinical condition thereof
CN113072540B (zh) * 2021-03-29 2023-07-14 贵州医科大学 一种靛玉红衍生的降解剂及其制备与应用
EP4329748A4 (de) * 2021-04-29 2025-10-22 Jawaharlal Nehru Centre For Advanced Scient Research Indirubinverbindungen und verfahren dafür

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987092B1 (en) 1999-04-12 2006-01-17 Faustus Forschungs Cie. Translational Cancer Research Gmbh Indigoid bisindole derivatives
AU2004285522A1 (en) 2003-10-28 2005-05-12 Centre National De La Recherche Scientifique Indirubin-type compounds, compositions, and methods for their use
JP5448455B2 (ja) * 2005-12-23 2014-03-19 サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク （セ エン エール エス） 新規３’−，７−置換インジルビンおよびそれらの適用
EP2149553B1 (de) 2008-08-01 2011-10-19 Centre National de la Recherche Scientifique 3',6-substituierte Indirubine und ihre biologischen Anwendungen

Also Published As

Publication number Publication date
JP2011529873A (ja) 2011-12-15
WO2010013168A1 (en) 2010-02-04
ATE547401T1 (de) 2012-03-15
CA2732232A1 (en) 2010-02-04
CA2732232C (en) 2017-11-07
EP2328866B1 (de) 2012-02-29
EP2149553A1 (de) 2010-02-03
JP5577336B2 (ja) 2014-08-20
US20110136808A1 (en) 2011-06-09
US8829203B2 (en) 2014-09-09
EP2328866A1 (de) 2011-06-08
EP2149553B1 (de) 2011-10-19

Similar Documents

Publication Publication Date Title
ATE547401T1 (de) 3',6-substituierte indirubine und ihre biologische anwendung
BRPI0606524A2 (pt) derivados de indol para o tratamento de infecções virais
MX2010001170A (es) Derivados de imidazolona, metodo de preparacion de los mismos y uso biologico de los mismos.
CY1109727T1 (el) Παραγωγα ν3 αλκυλιωμενου βενζιμιδαζολιου ως αναστολεις μεκ
EA201001124A1 (ru) Производные хинолина и их применение в качестве фунгицидов
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
MY149934A (en) 4-substituted phenoxyphenylacetic acid derivatives
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
CO6241115A2 (es) Compuestos y composiciones como inhibidores de protein quinasas
NZ596538A (en) Haloalkyl heteroaryl benzamide compounds
BRPI1009235A8 (pt) acetamidas substítuidas por 2-(hetero)arila, n-(hetero)arila e seus usos, e composição farmacêutica
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA201170176A1 (ru) Ингибитор stat3, содержащий хинолинкарбоксамидное производное в качестве активного ингредиента
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
NO20082096L (no) Azaindol-2-karboksamidderivativer
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
EA200700286A1 (ru) Применение замещённых производных 2-пирролидона в качестве фунгицидов и инсектицидов
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
JOP20200326A1 (ar) مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها
EA201000069A1 (ru) Новые гербициды
EA200801068A1 (ru) Производные четвертичного альфа-аминокарбоксамида в качестве модуляторов потенциалозависимых натриевых каналов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties